Literature DB >> 8039872

Construction and characterization of recombinant Vibrio cholerae strains producing inactive cholera toxin analogs.

C C Häse1, L S Thai, M Boesman-Finkelstein, V L Mar, W N Burnette, H R Kaslow, L A Stevens, J Moss, R A Finkelstein.   

Abstract

The catalytic A subunit of cholera toxin (CT-A) is capable of ADP-ribosylating the guanine nucleotide-binding protein, which regulates cell adenylyl cyclase, leading to the life-threatening diarrhea of cholera. Amino acids involved in the enzymatic activity of CT-A have previously been identified. By means of site-directed mutagenesis, an analog of the CT-A subunit gene was created with codon substitutions for both Arg-7 and Glu-112, each of which has been shown to produce subunits lacking ADP-ribosyltransferase activity. The mutated gene fragment was exchanged for the wild-type copy in the previously cloned ctxAB operon from El Tor biotype, Ogawa serotype Vibrio cholerae strain 3083, which produces CT-2. Further, the zonula occludens toxin gene, zot, was inactivated by an insertional mutation to create the new plasmid construct pCT-2*. Additionally, a DNA fragment encoding the B subunit of CT-1 (CT produced by classical biotype, Inaba serotype V. cholerae strain 569B) was exchanged for the homologous part in pCT-2*, resulting in the creation of pCT-1*. These plasmid constructs were introduced into the CT-negative V. cholerae mutant strain JBK70 (E1 Tor biotype, Inaba serotype); CT-A-B+ derivatives CVD101 and CVD103 of classical biotype Ogawa and Inaba serotype strains 395 and 569B, respectively; El Tor biotype Inaba and Ogawa serotype strains C6706 and C7258, respectively, recently isolated in Peru; and O139 (synonym Bengal) strain SG25-1 from the current epidemic in India. Recombinant toxins (CT-1* and CT-2*), partially purified from culture supernatants of transformed JBK70, were shown to be inactive on mouse Y1 adrenal tumor cells and in an in vitro ADP-ribosyltransferase assay. CT-1* and CT-2* reacted with polyclonal and monoclonal antibodies against both A and B subunits of CT. The toxin analogs reacted with antibodies against CT-A and CT-B on cellulose acetate strips and in a GM1 enzyme-linked immunosorbent assay; they reacted appropriately with B-subunit epitype-specific monoclonal antibodies in checkerboard immunoblots, and they formed precipitin bands with GM1-ganglioside in Ouchterlony tests. However, the reactions of the modified proteins with anti-A-subunit monoclonal antibodies were weaker than the reactions with wild-type holotoxins. V, cholerae strains carrying ctxA*, with either ctxB-1 or ctxB-2, and inactivated zot genes were created by homologous recombination. The recombinant strains and the purified toxin analogs were inactive in the infant rabbit animal model.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8039872      PMCID: PMC302926          DOI: 10.1128/iai.62.8.3051-3057.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  39 in total

1.  A rapid alkaline extraction procedure for screening recombinant plasmid DNA.

Authors:  H C Birnboim; J Doly
Journal:  Nucleic Acids Res       Date:  1979-11-24       Impact factor: 16.971

2.  Origin of the enzymatically active A1 fragment of cholera toxin.

Authors:  D M Gill; R S Rappaport
Journal:  J Infect Dis       Date:  1979-06       Impact factor: 5.226

3.  Pathogenesis of experimental cholera: biologic ativities of purified procholeragen A.

Authors:  R A Finkelstein; P Atthasampunna; M Chulasamaya; P Charunmethee
Journal:  J Immunol       Date:  1966-03       Impact factor: 5.422

4.  Adjuvant effect of cholera enterotoxin on the immune response of the mouse to sheep red blood cells.

Authors:  R S Northrup; A S Fauci
Journal:  J Infect Dis       Date:  1972-06       Impact factor: 5.226

5.  "Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate--polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A.

Authors:  W N Burnette
Journal:  Anal Biochem       Date:  1981-04       Impact factor: 3.365

6.  Procholeragenoid: an aggregated intermediate in the formation of choleragenoid.

Authors:  R A Finkelstein; K Fujita; J J LoSpalluto
Journal:  J Immunol       Date:  1971-10       Impact factor: 5.422

7.  Test for enterotoxigenic Escherichia coli using Y-1 adrenal cells in miniculture.

Authors:  D A Sack; R B Sack
Journal:  Infect Immun       Date:  1975-02       Impact factor: 3.441

8.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

9.  Characterization and distribution of the hemagglutinins produced by Vibrio cholerae.

Authors:  L F Hanne; R A Finkelstein
Journal:  Infect Immun       Date:  1982-04       Impact factor: 3.441

10.  Safety and immunogenicity of live oral cholera vaccine candidate CVD 110, a delta ctxA delta zot delta ace derivative of El Tor Ogawa Vibrio cholerae.

Authors:  C O Tacket; G Losonsky; J P Nataro; S J Cryz; R Edelman; A Fasano; J Michalski; J B Kaper; M M Levine
Journal:  J Infect Dis       Date:  1993-12       Impact factor: 5.226

View more
  7 in total

1.  Construction of nontoxic derivatives of cholera toxin and characterization of the immunological response against the A subunit.

Authors:  M R Fontana; R Manetti; V Giannelli; C Magagnoli; A Marchini; R Olivieri; M Domenighini; R Rappuoli; M Pizza
Journal:  Infect Immun       Date:  1995-06       Impact factor: 3.441

2.  Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection.

Authors:  Pallavi R Manuri; Bharti Nehete; Pramod N Nehete; Rose Reisenauer; Seth Wardell; Amy N Courtney; Ratish Gambhira; Dakshyani Lomada; Ashok K Chopra; K Jagannadha Sastry
Journal:  Vaccine       Date:  2007-01-24       Impact factor: 3.641

3.  Antibody against the capsule of Vibrio cholerae O139 protects against experimental challenge.

Authors:  D K Sengupta; M Boesman-Finkelstein; R A Finkelstein
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

4.  Cholera toxin B subunit activates arachidonic acid metabolism.

Authors:  J W Peterson; R A Finkelstein; J Cantu; D L Gessell; A K Chopra
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

5.  Structural inferences for Cholera toxin mutations in Vibrio cholerae.

Authors:  Gunasagaran Shamini; Manickam Ravichandran; John T Sinnott; Charurut Somboonwit; Harcharan S Sidhu; Paul Shapshak; Pandjassarame Kangueane
Journal:  Bioinformation       Date:  2011-03-02

6.  Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity.

Authors:  B L Dickinson; J D Clements
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

7.  Deciphering the possible role of ctxB7 allele on higher production of cholera toxin by Haitian variant Vibrio cholerae O1.

Authors:  Arindam Naha; Rahul Shubhra Mandal; Prosenjit Samanta; Rudra Narayan Saha; Sreeja Shaw; Amit Ghosh; Nabendu Sekhar Chatterjee; Pujarini Dutta; Keinosuke Okamoto; Shanta Dutta; Asish Kumar Mukhopadhyay
Journal:  PLoS Negl Trop Dis       Date:  2020-04-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.